NCT02576561View on ClinicalTrials.gov

Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL

PHASE2UnknownINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

May 31, 2018

Study Completion Date

September 30, 2018

Conditions
Human PapillomavirusHigh-Grade Squamous Intraepithelial Lesions
Interventions
BIOLOGICAL

TVGV-1

Antigen + Adjuvant

BIOLOGICAL

GPI-0100

Adjuvant Alone

BIOLOGICAL

Placebo

Placebo

Trial Locations (11)

11777

ProHEALTH Care Associates LLP, Port Jefferson

19104

Penn Fertility Care/Reproductive Research Unit Univ of Pennsylvania, Philadelphia

23502

Insearch-Tidewater Clinical Research, Norfolk

27103

Unified Women's Clinical Research, Winston-Salem

27607

Unified Women's Clinical Research, Raleigh

30303

Grady Memorial Hospital, Atlanta

32127

Progressive Medical Research, Port Orange

33409

Comprehensive Clinical Trials, LLC, West Palm Beach

43231

Complete Healthcare for Women, Columbus

80228

Red Rocks OBGYN, Lakewood

85712

Visions Clinical Research - Tucson, Tucson

Sponsors
All Listed Sponsors
collaborator

Clinical Research Management, Inc.

INDUSTRY

lead

THEVAX Genetics Vaccine

INDUSTRY